SCHEMBL26634748

SCHEMBL26634748

CCC(CC)C1(C)CCN(C(C)=O)C1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.36
CYP3A4 P08684 3/20 0.35
PIK3CD O00329 1/20 0.34
ALDH1A1 P00352 4/20 0.34
CYP2C19 P33261 2/20 0.34
MAPK1 P28482 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRL1 P41146 1/20 0.34
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
TSHR P16473 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP2D6 P10635 5/20 0.33
CYP2C9 P11712 3/20 0.33
CYP1A2 P05177 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
USP2 O75604 3/20 0.32
EPHX2 P34913 1/20 0.32
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17172988 0.79 SMN1; SMN2 (0.39) SMN1; SMN2CYP3A4PIK3CDALDH1A1CYP2C19
SCHEMBL24317731 0.79 SMN1; SMN2 (0.39) SMN1; SMN2CYP3A4PIK3CDALDH1A1CYP2C19
SCHEMBL12921202 0.79 SMN1; SMN2 (0.39) SMN1; SMN2CYP3A4PIK3CDALDH1A1CYP2C19
SCHEMBL26053285 0.78 SMN1; SMN2 (0.38) SMN1; SMN2CYP3A4PIK3CDALDH1A1CYP2C19
SCHEMBL25708741 0.78 SMN1; SMN2 (0.38) SMN1; SMN2CYP3A4PIK3CDALDH1A1CYP2C19
SCHEMBL13892470 0.75 CYP2D6 (0.37) SMN1; SMN2CYP3A4PIK3CDALDH1A1CYP2C19
SCHEMBL26634753 0.75 CYP4F2 (0.35) SMN1; SMN2CYP3A4PIK3CDALDH1A1CYP2C19
SCHEMBL4815629 0.72 SMN1; SMN2 (0.46) SMN1; SMN2CYP3A4ALDH1A1CYP2C19MAPK1
SCHEMBL4815638 0.72 SMN1; SMN2 (0.46) SMN1; SMN2CYP3A4ALDH1A1CYP2C19MAPK1
SCHEMBL13819904 0.72 SMN1; SMN2 (0.39) SMN1; SMN2CYP3A4PIK3CDALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 SMN1; SMN2 1860/4885CYP3A4 2637/4885PIK3CD 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.